The IPO Buzz: AgomAb Therapeutics (AGMB) Prices IPO at $16 & Joins ‘The Mid-Point Club’
Mid-point pricing is the trend. AgomAb Therapeutics NV (AGMB), a Belgian biotech backed by Pfizer, priced its IPO at $16.00 – the mid-point of its range – last night. That put AgomAb Therapeutics right in step with SpyGlass Pharma (SGP) and Jennifer Garner’s Once Upon a Farm (OFRM) – both IPOs also priced at the mid-point of their respective ranges last night – after a brutal..
Read more February 6, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| AgomAb Therapeutics | AGMB | 12.5 | $ 200.0 mil | 2/6/2026 Priced | S/O | S/O |
| Cambridge Acquisition | CAQU | 20.0 | $ 200.0 mil | 2/6/2026 Priced | S/O | S/O |
| Once Upon a Farm, PBC | OFRM | 11.0 | $ 198.0 mil | 2/6/2026 Priced | S/O | S/O |
Last 100 IPOs - February 5, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 51 |
| Number Down: | 44 |
| Number Unchanged: | 5 |
| Percentage Change From Issue Price: | -7.81% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - February 5, 2026
| Number of IPOs priced (Excluding 26 units) : | 18 |
| Number Up: | 7 |
| Number Down: | 9 |
| Number Unchanged: | 2 |
| Total Return From Issue Price: | -17.00% |
| The Nasdaq Composite Index YTD % Change | 35.22% |